A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)

Our findings suggest an improvement in small bowel transit, small bowel response to food and a reduction in colonic volume after starting ETI. These effects may relate to CFTR activation in the small bowel. To our knowledge this is the first study to show a physiological change in GI transit and function in response to CFTR modulator use through imaging studies.

Authors

Institutions

Publication Details

Journal
Journal of Cystic Fibrosis
Published
2024-09-01
DOI
https://doi.org/10.1016/j.jcf.2024.08.001
Citations
5
Primary Topic
Cystic Fibrosis Research Advances
Type
article
Field-Weighted Citation Impact
2.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)

H. Barr, Luca Marciani, Neele Dellschaft, Carlos Zagoya et al.
5 citations
Journal of Cystic Fibrosis
Cystic Fibrosis Research Advances
2.09
article

A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)

H. Barr, Luca Marciani, Neele Dellschaft, Carlos Zagoya, Robert E. Spiller, Iain D. Stewart, Jochen G. Mainz, Alexander Yule, Caroline L. Hoad, Alan R Smyth, Giles Major, Penny Anne Gowland, Christabella Ng, A. Flores Recto, Florence Lockwood
article en
5 citations

Abstract

Our findings suggest an improvement in small bowel transit, small bowel response to food and a reduction in colonic volume after starting ETI. These effects may relate to CFTR activation in the small bowel. To our knowledge this is the first study to show a physiological change in GI transit and function in response to CFTR modulator use through imaging studies.

Journal of Cystic FibrosisVol. 23(5)
Nottingham University Hospitals NHS Trust (GB), University of Nottingham (GB), Centre Hospitalier Universitaire Vaudois (CH), Lung Institute (US), NIHR Imperial Biomedical Research Centre (GB), Nottingham Biomedical Research Centre (GB), Universitätsklinikum Brandenburg an der Havel (DE)
Vertex Pharmaceuticals, Nottingham University Hospitals NHS Trust, University of Nottingham
Openalex Percentile: Top 12%
Cystic Fibrosis Research Advances
2.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.